Agios Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Agios Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Agios Pharmaceuticals, Inc. (NAS: AGIO) , today announced that David Schenkein, M.D., chief executive officer, will present at the Morgan Stanley Global Healthcare conference on Wednesday, September 11, 2013 at 11:45 a.m. ET in New York City.
A live webcast of Agios' presentation can be accessed by visiting the investors section of the company's website at investor.agios.com. A replay of the webcast will be archived on the Agios website for two weeks following the presentation.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and rare metabolic genetic diseases (known as inborn errors of metabolism or IEMs) through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs advancing toward the clinic. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.
Agios Pharmaceuticals, Inc.
Media Contact:
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Glenn Goddard
investors@agios.com
KEYWORDS: United States North America Massachusetts New York
INDUSTRY KEYWORDS:
The article Agios Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
